134 related articles for article (PubMed ID: 8555646)
1. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
[TBL] [Abstract][Full Text] [Related]
2. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
3. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
5. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S
Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
9. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Wilson MJ; Sinha AA
Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
14. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
16. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression.
Kogianni G; Walker MM; Waxman J; Sturge J
Eur J Cancer; 2009 Mar; 45(4):685-93. PubMed ID: 19112015
[TBL] [Abstract][Full Text] [Related]
17. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
18. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Harvey SR; Nayak SK; Markus G; Ouhammouch M; Hemperly JJ; Dillman RO; Doyle DJ
Arch Biochem Biophys; 1997 Sep; 345(2):289-98. PubMed ID: 9308901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]